Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

74.30USD
17 Dec 2018
Change (% chg)

-- (--)
Prev Close
$74.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
329,831
52-wk High
$153.80
52-wk Low
$63.71

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  ALNY.OQ Industry Sector
P/E (TTM): -- 69.72 34.40
EPS (TTM): -5.12 -- --
ROI: -33.58 9.00 14.96
ROE: -39.86 10.14 16.53

Early approval of Alnylam's gene-silencing drug in question

Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data.

27 Sep 2018

UPDATE 4-Early approval of Alnylam's gene-silencing drug in question

* Co still plans to discuss potential early approval with FDA

27 Sep 2018

UPDATE 1-Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

10 Aug 2018

Alnylam's gene silencing drug wins FDA approval

Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

10 Aug 2018

Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

10 Aug 2018

Earnings vs. Estimates